This post is to notify any interested parties that I sold out of MNK at approximately $100 in late December. I had published an article in July 2014 regarding Acthar Gel shortly before QCOR and MNK merged in August. MNK has had significant upside after the merger. My investment in QCOR over the last couple of years was probably my most rewarding stock pick ever. Good luck to those who remain long (NYSE:MNK). The greatest opportunity, in my opinion, was when the shorts floated the scares of imminent problems which did not materialize with FDA ban, etc. As much criticism as the drug companies get, I am grateful for their role in discovering new ways to help humanity.
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.